Banner
Welcome to

Developmental Medicine

Share

Research

In Developmental Medicine, we remain committed to advancing care through rigorous clinical and scientific research.

In collaboration with Albert Einstein College of Medicine’s Children's Evaluation and Rehabilitation Center (CERC), our team has launched an array of research initiatives, many focused on investigating the underlying causes of autism, learning disabilities, cerebral palsy and other developmental disabilities.

These efforts have a clear, unswerving goal: to find cures and more effective treatments for these conditions by identifying their genetic, neurologic, physiologic and environmental etiologies. Once we understand these causes, the medical community will be empowered to take on these disabilities at the source, rather than treat the symptoms.

Beyond finding the bases of these problems, our research aims to evaluate and increase the efficacy of currently used treatments. We’re also actively involved in studies on physical rehabilitation, speech pathology, hearing and language development, social and behavioral adjustment, learning disabilities and more.

The Rose F. Kennedy Intellectual and Developmental Disabilities Research Center (IDDRC)

Specializing in intellectual and developmental disabilities in children and adolescents, the Rose F. Kennedy IDDRC serves as our central hub of research labs and patient clinics. For more than four decades, the IDDRC has been a vanguard of new research on brain development and function. Bridging the gap between academic research and clinical care, the scientists at IDDRC contribute landmark research on autism, Rett syndrome, Fragile X syndrome, Niemann-Pick C, seizure disorders, deafness, communication disorders and more.

The Rose F. Kennedy University Center for Excellence in Developmental Disabilities (UCEDD)

The Rose F. Kennedy UCEDD is dedicated to improving the lives of those with developmental disabilities. Along with offering direct services and providing interdisciplinary training, the UCEDD’s research focuses on creating, implementing and evaluating family-oriented strategies. By sharing this applied research openly with aligned agencies, Einstein’s UCEDD aims to enhance access to cutting-edge care for underserved communities.

Meet Sophie Molhom, director for research at CERC

Active Clinical Trials

Trial Description
Disease / Condition
Principal Investigator
Contact
Trial DescriptionA 12-Month, Open-Label, Repeat-Dose Safety Study of NRL-1 in Epilepsy Subjects - Click here for more information16-10-27-01
Disease/ConditionEpilepsy
Seizures
Neurology
Brain and Neurological
Principal InvestigatorAlexis Boro, MD
Contact Jeanne Gutierrez

Email Contact
Trial DescriptionA Phase II Multi-Center, Randomized, Double-Blind, 24-Week, Parallel Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Children and Adolescents Age 5-17 With Autism Spectrum Disorder (ASD) - Click here for more information16-10-117-01
Disease/ConditionAutism Spectrum Disorder
Neurodevelopmental Disorders
Pediatrics
Psychiatry - Non Cancer
Mental Health and Disorders
Principal InvestigatorEric Hollander, MD
Contact Danya Schlussel

Email Contact
Trial DescriptionAutism Genetics Network, Phase II: Increasing Representation of Human Diversity 2012-537
Disease/ConditionAutism Spectrum Disorder
Neurology
Pediatrics
Genetic Disorders
Principal InvestigatorSophie Molholm, PhD
Contact Danielle DeMaio
(718) 862-1860
Email Contact
Trial DescriptionCannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD) - Click here for more information2017-8538
Disease/ConditionChild Development
Neurodevelopmental Disorders
Autism Spectrum Disorder
Principal InvestigatorEric Hollander, MD
Contact Erin Shanahan

Email Contact
Trial DescriptionFollow-up study of children with early diagnosis of autism spectrum disorder IRB# 2007-546
Disease/ConditionAutism Spectrum Disorder
Principal InvestigatorLisa Shulman, MD
Contact Lisa Shulman, MD
(718) 430-3901
Email Contact
Trial DescriptionInfantile Spasms Multicenter Database IRB# 13-01-027
Disease/ConditionBrain and Neurological
Principal InvestigatorElissa Yozawitz, MD
Contact Elissa Yozawitz, MD
(718) 920-4378
Email Contact
Trial DescriptionMaintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma - Click here for more information10-07-196
Disease/ConditionBrain and Neurological
Principal InvestigatorLisa Gennarini, MD
Contact Joyce Brown

Email Contact
Trial DescriptionPhase 2 Study: Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Children and Adolescents With Prader-Willi Syndrome - Click here for more information2017-8076
Disease/ConditionPsychiatry - Non Cancer
Nervous System Diseases
Child Development
Pediatrics
Genetic Disorders
Principal InvestigatorEric Hollander, MD
Contact Danya Schlussel

Email Contact
Trial DescriptionSelf regulation in children with learning disabilities and inattention/hyperactivity IRB# 2006-425
Disease/ConditionChild Development
Principal InvestigatorKatherine Lawson, PhD
Contact Maria Valicenti-McDermott, MD
(718) 430-8600 6275
Email Contact
Trial DescriptionSensory Integration Therapy in Autism: Mechanisms and Effectiveness IRB# 2014-3795
Disease/ConditionAutism Spectrum Disorder
Principal InvestigatorSophie Molholm, PhD
Contact Maya Madzharova
(718) 862-1817
Email Contact
Trial DescriptionThe use of Complementary and Alternative Medicine in Autism IRB# 2007-371
Disease/ConditionAutism Spectrum Disorder
Principal InvestigatorMaria Valicenti-McDermott, MD
Contact Maria Valicenti-McDermott, MD
(718) 430-8600 Ext 6275
Email Contact
Trial DescriptionThe use of Virtual Reality Games to Enhance Therapy for Children with Cerebral Palsy. A pilot Study IRB# 2008-347
Disease/ConditionBrain and Neurological
Principal InvestigatorMaria Valicenti-McDermott, MD
Contact Maria Valicenti-McDermott, MD
(718) 430-8600 Ext 6275
Email Contact
Trial DescriptionVALENS: A Ph 1/2, Random'd, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate Safety/Preliminary Efficacy of AT342, an AAV8-Delivered Gene Transfer Therapy in Crigler-Najjar Syndrome Subjects Aged 1 Yr and Older - Click here for more information2017-7918
Disease/ConditionBrain and Neurological
Crigler-Najjar Syndrome
Gastroenterology & Liver Diseases
Heart and Vascular Diseases
Metabolic Diseases
Pediatrics
Principal InvestigatorNadia Ovchinsky, MD
Contact Sharon Thomas

Email Contact
View all Clinical Trials